Institutional Ownership
Maze Therapeutics Inc
CUSIP 578784100COMMAZEQ1 2026
13D / 13G Filings
20
Schedule 13D/13G on record
Beneficial Filers
8
Distinct reporting persons
Largest Stake
13.9%
Max % of class reported
Institutional Holders
161
13F filers (latest quarter)
Beneficial Owners — Schedule 13D / 13G
20 filings · latest Feb 13, 2026
| # | Filed | Reporting Person | Form | % of Class | Shares | Filing |
|---|---|---|---|---|---|---|
| 1 | Feb 13, 2026 | Frazier Life Sciences Public Fund, L.P. | 13G/A | 9.0% | 4.34M | SEC |
| 2 | Feb 13, 2026 | Third Rock Ventures IV, L.P. | 13G/A | 9.3% | 4.47M | SEC |
| 3 | Feb 6, 2026 | Gv 2019, L.P. | 13G/A | 2.9% | 1.39M | SEC |
| 4 | Nov 14, 2025 | Janus Henderson Group PLC | 13G/A | 7.3% | 3.21M | SEC |
| 5 | Nov 14, 2025 | Foresite Capital Fund IV, L.P. | 13G/A | 11.0% | 608.9K | SEC |
| 6 | Nov 13, 2025 | Matrix Capital Management Company, LP | 13G/A | 3.5% | 1.65M | SEC |
| 7 | Aug 14, 2025 | Frazier Life Sciences Public Fund, L.P. | 13G/A | 7.7% | 3.35M | SEC |
| 8 | Aug 14, 2025 | Janus Henderson Group PLC | 13G/A | 6.0% | 2.63M | SEC |
| 9 | Aug 14, 2025 | Deep Track Capital, LP | 13G/A | 9.0% | 3.95M | SEC |
| 10 | May 15, 2025 | Arch Venture Fund X, L.P. | 13G | 9.4% | 4.12M | SEC |
10 more beneficial-ownership filings on Premium
See the full Schedule 13D/13G history for Maze Therapeutics Inc.
Unlock full historyTop Institutional Holders (13F)
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Frazier Life Sciences Management, L.P. | 4.57M | $136.33M |
| 2 | Trv Gp IV, LLC | 4.47M | $133.55M |
| 3 | Arch Venture Management, LLC | 4.12M | $122.98M |
| 4 | Deep Track Capital, LP | 3.48M | $103.81M |
| 5 | Janus Henderson Group PLC | 2.86M | $85.28M |
| 6 | Paradigm Biocapital Advisors LP | 2.74M | $81.92M |
| 7 | Blackrock, Inc. | 2.57M | $76.73M |
| 8 | A16z Capital Management, L.L.C. | 1.70M | $50.81M |
| 9 | Venrock Adviser, LLC | 1.60M | $47.82M |
| 10 | Alphabet Inc. | 1.39M | $41.45M |